---
type: claim
domain: health
description: Omada's data shows behavioral support creates durable outcomes independent of continued medication use, reframing the value proposition from medication management to lasting behavioral change
confidence: experimental
source: Omada Health clinical outcomes data, March 2026 announcement
created: 2026-05-02
title: Behavioral GLP-1 companion programs achieve 0.8 percent average weight change at one year post-discontinuation versus 11-12 percent regain in clinical trials proving standalone behavioral value
agent: vida
sourced_from: health/2026-03-05-omada-glp1-flex-care-employer-cash-pay-model.md
scope: causal
sourcer: Omada Health
supports: ["comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation"]
related: ["glp1-long-term-persistence-ceiling-14-percent-year-two", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation"]
---

# Behavioral GLP-1 companion programs achieve 0.8 percent average weight change at one year post-discontinuation versus 11-12 percent regain in clinical trials proving standalone behavioral value

Omada Health reports that members who discontinued GLP-1 receptor agonists but continued behavioral support showed 0.8% average weight change at one year, compared to 11-12% weight regain observed in clinical trials without behavioral support (STEP-1 extension data). This 10-14x difference in post-discontinuation outcomes demonstrates that the behavioral companion program has standalone value independent of medication persistence. The clinical significance is that behavioral support is not merely medication adherence scaffolding but a durable intervention that modifies eating patterns, activity levels, and metabolic health even after pharmacological support ends. This evidence supports the economic viability of the Flex Care model: employers are purchasing lasting behavioral change, not just medication management infrastructure. The data comes from Omada's real-world member population, not a randomized trial, so selection effects may exist (members who continue behavioral support post-discontinuation may differ from those who don't). However, the magnitude of the difference (0.8% vs. 11-12%) is large enough to suggest a genuine effect beyond selection. This reframes the GLP-1 behavioral support value proposition: instead of 'helping people stay on expensive medications,' it becomes 'creating durable metabolic and behavioral improvements that persist even if medication access is lost.' This is critical for the cash-pay model's viability—if behavioral support only worked while patients were on medication, employers would have no reason to fund it separately.
